Background
Smoking is a serious public health problem, contributing significantly to the risk of death from cancers, cardiovascular diseases, lung disorders and stroke. Public health agencies aim to reduce tobacco use; however, relapse is common during smoking treatment programs. According to the World Health Organization, if current trends continue, the annual number of deaths from diseases related to smoking could double from five million in 2000 to 10 million in 2020 [
1,
2].
Studies have shown that although smoke toxicity is related to many components of the cigarette, nicotine is responsible for the development of dependence [
3,
4]. Smokers in Brazil who want to quit have the following first-line pharmacological treatments: nicotine replacement therapy (NRT), bupropion (an inhibitor of the reuptake of norepinephrine, dopamine and nicotinic antagonist) and, varenicline (a partial agonist of nicotinic acetylcholine receptor - nAChR - α4β2) [
5‐
7].
Cigarette smoking is classified as a complex behavior comprising multiple stages such as initiation, experimentation, regular use, addiction, cessation and relapse [
8,
9]. To better understand the role played by genes in those stages, twin studies, and allelic association studies of candidate genes and large genome wide-association studies are increasingly required [
8‐
10].
In the last ten years, several studies have identified
loci, mainly in chromosome 8 and 15, which are highly involved in the pathogenesis of nicotine dependence (ND) process. These regions of the genome include genes encoding various subunits of the nAChR. These receptors are expressed in the brain and are thought to be responsible for mediating the addictive effects of nicotine [
1,
8,
10‐
14]. Therefore, studies have shown the association of polymorphisms in genes encoding the subunits of nicotinic receptors (
CHRNA2,
CHRNA3,
CHRNA5,
CHRNB3) with the number of cigarettes per day, ND and risk for developing lung cancer [
1,
8,
13,
15,
16].
In the context of personalized medicine, the aims of the present study were to evaluate whether CHRNA2, CHRNA3, CHRNA5 and, CHRNB3 polymorphisms were associated with level of dependency and, response to smoking cessation therapies in patients from a smoking cessation assistance program.
Discussion
The main findings of this study was the association of GA and AA genotypes for both
CHRNA5 rs16969968 and rs2036527 polymorphisms with increased success rate in smoking cessation treatment in women. Many studies have identified the association of polymorphisms in the
CHRNA5-A3-B4 gene with smoking cessation in response to smoking cessation therapies [
2,
29‐
31]. Recently, our group of researchers found the association of the
CHRNA4 rs10443196 and cytochrome P450 2B6 (
CYP2B6) 785A > G polymorphisms with a higher success rate in varenicline and bupropion treatment, respectively [
32,
33].
The association of the
CHRNA5 rs16969968 polymorphism with higher rates of success in smoking cessation treatment in women is corroborated by previous studies. As shown in vitro experiments Bierut et al. [
14] and Kuryatov et al. [
34], individuals carrying the allele A may express nAChR subtypes composed by α5 subunits with reduced function. Bergen et al. [
35] showed that a lower frequency of the allele for rs1051730, which is in strong linkage disequilibrium with rs16969968, was associated with a higher withdrawal rate with NRT. Bergen et al. pointed out that smokers with reduced function of the α5 subunit and associated with increased ND may have greater difficulty quitting. However, they suggested that the prescription of NRT can improve cognitive performance in smoking abstinence, maintaining the normal functioning of the brain after quitting, and this effect may be stronger for individuals with the rs1051730 risk allele. Similarly, Chen et al. [
36] reported that individuals with the AA genotype for the rs16969968 had higher withdrawal rate in the treatment with NRT. In the study by Jensen et al. [
37], the A allele was associated with lower rates of aversive effects to the nicotine and also with improvement in cognitive control. Jensen et al. suggested that the A allele may be important in tolerability and in response to treatments with NRT. They added that, remarkably, the α5 subunit plays an essential role in mediating aversive effects to the nicotine. Interestingly, King et al. [
31] showed the association of others risk alleles for ND in
locus chr15q25 with lower incidence of nausea. The authors suggest that this may be explained by the tolerance, because individuals with higher ND have higher daily intake of nicotine, are more tolerant and therefore are less likely to experience nausea in response to a nicotinic partial agonist such as varenicline. Therefore, reduced function of the α5 subunit, the higher tolerability of NRT and varenicline and improvement of cognitive control may be possible explanations for the association of rs16969968 with success in this study. One other possibility is that the rs16969968 can be in linkage disequilibrium with other functional polymorphisms that could be involved in smoking cessation process and/or mechanisms in response to the NRT.
There was a higher frequency of depression and/or anxiety in the women’s group, which according to some studies could reduce success rates in the smoking cessation treatment [
38‐
42]. Zawertailo et al. [
38] conducted a study of 13,000 smokers and found that individuals with recurrent depression were significantly less likely to quit smoking compared to those with no history of depression. Goodwin et al. [
39] found that panic attacks and social anxiety disorder were more likely in female smokers than male smokers. Stepankova et al. [
40], in a study of 1730 smokers, found that 289 had a history of depression. The tobacco abstinence rate at 1 year was 32.5% for smokers with a history of depression and 38.7% for those with no history. In our study, although the frequencies of depression and anxiety were higher in women than in men, these variables were not associated with treatment outcome and rs16969968 and rs2036527 polymorphisms remained significantly associated with smoking cessation in a multivariate model.
There are evidences that gender can be an important factor in smoking cessation process. Beltz et al. [
43], evaluating functional magnetic resonance imaging and behavioral data from 50 adult daily smokers (23 women), found that women had an increased nicotine tolerance when compared to men. Smith et al. [
44] found that women were 31% less likely to quit smoking than men. Pierce et al. [
45] reported significant sex differences in smoking cessation. They observed the women had weight gain, higher prevalence of depression disorders and increased need of social support to stop smoking.
Some studies showed that several factors may influence sex/gender differences [
46], such as biopsychosocial factors, menstrual cycle, hormonal [
47,
48], having children or not, and smoking cessation medication [
44,
49].
In the present study, we found no association of
CHRNA2 rs2472553,
CHRNA3 rs1051730 and
CHRNB3 rs6474413 polymorphisms with treatment outcome. The results of our study corroborate the findings of previous studies. Ruyck et al. [
50] and Sarginson et al. [
2] found no association for rs1051730 with outcome of treatment. However, Munafo et al. [
51] identified the T allele associated with decreased likelihood of smoking cessation. Bergen et al. [
35] associated the T allele with higher withdrawal rates with NRT and lower withdrawal rate in placebo treatment.
Regarding FTND score, several studies have identified the association of polymorphisms in genes encoding nAChR alpha and beta subunits with FTND and, number of cigarettes per day [
52‐
57]. However, our study found no significant association of the polymorphisms studied with FTND, consistent with the findings of previous studies, which found no association of
CHRNA3 rs1051730,
CHRNA5 rs16969968,
CHRNA5 rs2036527 or
CHRNA5 rs6474413 polymorphisms with phenotypes related to smoking, including ND [
58‐
62].
Etter et al. [
62] suggested that the reason for missing association of polymorphisms studied, including rs16969968, can be explained by the difference in the methods used, or due to the small sample size. Amos et al. [
61] did not find association of rs16969968 polymorphism with smoking behavior in either African American case patients or African American control participants. The authors point out some limitations of no association with the studied phenotypes, as the sample size limited and also because individuals come from a single center; it is possible that some degree of population structure influenced the findings.
There are some limitations in our study that should be mentioned. First, most patients treated at the PAF were classified as moderately or highly dependent, which may have affected the analysis of association between genotypes and FTND score. Second, the race/color of patients was self-report and we did not performed genetic ancestry. Third, we did not perform the correction of P values for multiple testing. Fourth, besides the available variables used in the multivariate models other relevant factors that could be important, such as the functionality of the receptors, motivation to quit smoking, biopsychosocial and others factors related to sex/gender, could have influenced the results.